US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Therapeutics

29.00

-0.5800-1.96%

Post-market: 29.000.00000.00%19:54 EDT

Volume:156.51K

Turnover:4.55M

Market Cap:816.24M

PE:-16.39

High:29.52

Open:28.80

Low:28.57

Close:29.58

Loading ...

Overview Company News Filings

Travere Therapeutics asumed with a Buy at H.C. Wainwright

Ocumension Therapeutics Gets China Nod for Phase 3 Trial of Presbyopia Drug

MT Newswires Live

PYC Therapeutics Says Safety Review Committee Approves Dose Escalation in Autosomal Dominant Optic Atrophy Study

MT Newswires Live

PYC Therapeutics Advances ADOA Clinical Trial with Dose Escalation Approval

LENZ Therapeutics Holds 2025 Annual Stockholders Meeting

Xilio Therapeutics Expands Board with New Director

Lenz Therapeutics Inc. Concluded Annual Stockholders Meeting

Cautious Outlook for Mineralys Therapeutics Amid Market Challenges and Competitive Pressures

Kazia Therapeutics Reports Half-Year Financials Amidst Ongoing Drug Development

Press Release: MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Keros Therapeutics Hindered by KER-065 Concerns Despite 'Intriguing' Pipeline, BofA Says

MT Newswires Live

Vera Therapeutics Inc call volume above normal and directionally bullish

BofA Securities Downgrades Keros Therapeutics to Neutral From Buy, Adjusts Price Target to $18 From $32

MT Newswires Live

Buy Rating for Unicycive Therapeutics: Strong Market Potential Despite Vendor Compliance Issue

Unicycive Therapeutics Faces FDA Compliance Delay

Ernexa Therapeutics announces 1-for-15 reverse stock split

Keros Therapeutics Cut to Neutral From Buy by B of A Securities

Windtree Therapeutics announces agreement to acquire Titan Environmental

Optimistic Outlook for Summit Therapeutics: Buy Rating Affirmed Despite OS Miss in HARMONi Trial

Keros Therapeutics: Strategic Initiatives and Capital Return Signal Potential Upside

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/LENZ/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"LENZ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":29,"timestamp":1749844800000,"preClose":29.58,"halted":0,"volume":156505,"hourTrading":{"tag":"盘后","latestPrice":29,"preClose":29,"latestTime":"19:54 EDT","volume":608,"amount":17570.81,"timestamp":1749858862399},"delay":0,"floatShares":11653723,"shares":28146154,"eps":-1.769251,"marketStatus":"Market Closed","change":-0.58,"latestTime":"06-13 16:00:00 EDT","open":28.8,"high":29.52,"low":28.565,"amount":4554492.6963,"amplitude":0.032285,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.769251,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1750060800000},"marketStatusCode":7,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":29.58,"preHourTrading":{"tag":"盘前","latestPrice":28.84,"preClose":29.58,"latestTime":"09:29 EDT","volume":77,"amount":2235.719948,"timestamp":1749821370092},"postHourTrading":{"tag":"盘后","latestPrice":29,"preClose":29,"latestTime":"19:54 EDT","volume":608,"amount":17570.81,"timestamp":1749858862399},"volumeRatio":0.299098,"impliedVol":0.5592,"impliedVolPercentile":0.5435},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LENZ\",,,,,undefined,":{"symbol":"LENZ","floatShares":11653723,"roa":"-17.75%","roe":"-24.47%","lyrEps":-2.338654,"volumeRatio":0.299098,"shares":28146154,"dividePrice":0,"high":29.52,"amplitude":0.032285,"preClose":29.58,"low":28.565,"week52Low":16.28,"pbRate":"4.25","week52High":38.93,"institutionHeld":0,"latestPrice":29,"eps":-1.769251,"divideRate":0,"volume":156505,"delay":0,"ttmEps":-1.769251,"open":28.8,"prevYearClose":28.87,"prevWeekClose":31.96,"prevMonthClose":29.2,"prevQuarterClose":25.71,"fiveDayClose":31.96,"twentyDayClose":27.34,"sixtyDayClose":25.52},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LENZ\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2542833245","title":"Travere Therapeutics asumed with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2542833245","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542833245?lang=en_us&edition=fundamental","pubTime":"2025-06-11 18:10","pubTimestamp":1749636647,"startTime":"0","endTime":"0","summary":"H.C. Wainwright assumed coverage of Travere Therapeutics (TVTX) with a Buy rating and $30 price target The primary focus is the Filspari commercial...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/travere-therapeutics-asumed-with-a-buy-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/travere-therapeutics-asumed-with-a-buy-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","LENZ","BK4139","BK4007","TVTX"],"gpt_icon":0},{"id":"2542091300","title":"Ocumension Therapeutics Gets China Nod for Phase 3 Trial of Presbyopia Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2542091300","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542091300?lang=en_us&edition=fundamental","pubTime":"2025-06-11 17:57","pubTimestamp":1749635838,"startTime":"0","endTime":"0","summary":"China's medical products administrator accepted Ocumension Therapeutics'  phase 3 clinical trial application for its OT-802 pilocarpine hydrochloride drug for presbyopia or loss of focus of the eye.The drug showed a favorable safety profile in preclinical studies, according to a Tuesday filing with the Hong Kong bourse.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01477","BK4539","BK4139","BK4007","BK1574","BK1191","LENZ"],"gpt_icon":0},{"id":"2542373795","title":"PYC Therapeutics Says Safety Review Committee Approves Dose Escalation in Autosomal Dominant Optic Atrophy Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2542373795","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542373795?lang=en_us&edition=fundamental","pubTime":"2025-06-11 11:23","pubTimestamp":1749612188,"startTime":"0","endTime":"0","summary":"PYC Therapeutics  said that the safety review committee monitoring the single ascending dose study of its drug candidate PYC-001 for patients with autosomal dominant optic atrophy approved an increase in the dose, according to a Wednesday Australian bourse filing.The committee approved an increase in the dose to be administered to patients in groups two and three to 30 micrograms per eye from 10 micrograms, following an evaluation of four-week follow-up data.The study will be followed by a multiple ascending dose study and an open-label extension study, facilitating repeat dosing and the evaluation of the optimal dosing regimen, safety, tolerability, and efficacy profile.The company's shares shed 1% in recent Wednesday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4539","BK4139","PYC.AU","LENZ","BK7067"],"gpt_icon":0},{"id":"2542532671","title":"PYC Therapeutics Advances ADOA Clinical Trial with Dose Escalation Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2542532671","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542532671?lang=en_us&edition=fundamental","pubTime":"2025-06-11 08:12","pubTimestamp":1749600776,"startTime":"0","endTime":"0","summary":"PYC Therapeutics Limited ( ($AU:PYC) ) has provided an announcement. PYC Therapeutics has received approval from the Safety Review Committee to esc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/pyc-therapeutics-advances-adoa-clinical-trial-with-dose-escalation-approval?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/pyc-therapeutics-advances-adoa-clinical-trial-with-dose-escalation-approval?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4007","BK4539"],"gpt_icon":0},{"id":"2542553328","title":"LENZ Therapeutics Holds 2025 Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2542553328","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542553328?lang=en_us&edition=fundamental","pubTime":"2025-06-11 05:18","pubTimestamp":1749590337,"startTime":"0","endTime":"0","summary":"The latest update is out from LENZ Therapeutics ( ($LENZ) ). LENZ Therapeutics, Inc. held its 2025 annual meeting of stockholders on June 10, 2025....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lenz-therapeutics-holds-2025-annual-stockholders-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lenz-therapeutics-holds-2025-annual-stockholders-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4007","BK4139","BK4539"],"gpt_icon":0},{"id":"2542320328","title":"Xilio Therapeutics Expands Board with New Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2542320328","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542320328?lang=en_us&edition=fundamental","pubTime":"2025-06-11 05:03","pubTimestamp":1749589394,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics ( ($XLO) ) has provided an announcement. On June 10, 2025, Xilio Therapeutics expanded its Board of Directors to ten members by ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xilio-therapeutics-expands-board-with-new-director?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xilio-therapeutics-expands-board-with-new-director?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","BK4139","XLO","BK4007"],"gpt_icon":0},{"id":"2542404153","title":"Lenz Therapeutics Inc. Concluded Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2542404153","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542404153?lang=en_us&edition=fundamental","pubTime":"2025-06-11 04:56","pubTimestamp":1749588964,"startTime":"0","endTime":"0","summary":"Lenz Therapeutics Inc. held its annual stockholders meeting on June 10, 2025. The election of Class III and Class I directors was approved, with Kimberlee C. Drapkin, Zach Scheiner, Frederic Guerard, and James McCollum elected. Additionally, the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lenz Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 10, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL2dN0PG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","LENZ","BK4139"],"gpt_icon":0},{"id":"2542583340","title":"Cautious Outlook for Mineralys Therapeutics Amid Market Challenges and Competitive Pressures","url":"https://stock-news.laohu8.com/highlight/detail?id=2542583340","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542583340?lang=en_us&edition=fundamental","pubTime":"2025-06-11 04:35","pubTimestamp":1749587713,"startTime":"0","endTime":"0","summary":"Mineralys Therapeutics, Inc. (MLYS) has received a new Hold rating, initiated by Jefferies analyst, Dennis Ding. Dennis Ding has given his Hold rat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cautious-outlook-for-mineralys-therapeutics-amid-market-challenges-and-competitive-pressures-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cautious-outlook-for-mineralys-therapeutics-amid-market-challenges-and-competitive-pressures-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","BK4007","BK4539","MLYS"],"gpt_icon":0},{"id":"2542834055","title":"Kazia Therapeutics Reports Half-Year Financials Amidst Ongoing Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2542834055","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542834055?lang=en_us&edition=fundamental","pubTime":"2025-06-11 04:27","pubTimestamp":1749587243,"startTime":"0","endTime":"0","summary":"Kazia Therapeutics ( ($KZIA) ) just unveiled an update. On June 9, 2025, Kazia Therapeutics reported its unaudited half-year results for the period...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kazia-therapeutics-reports-half-year-financials-amidst-ongoing-drug-development?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kazia-therapeutics-reports-half-year-financials-amidst-ongoing-drug-development?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4007","BK4539"],"gpt_icon":0},{"id":"2542534112","title":"Press Release: MiNK Therapeutics Announces Virtual Annual Shareholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2542534112","media":"Dow Jones","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542534112?lang=en_us&edition=fundamental","pubTime":"2025-06-11 01:33","pubTimestamp":1749576780,"startTime":"0","endTime":"0","summary":"NEW YORK, June 10, 2025  -- MiNK Therapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T  cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 18, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","LENZ","INKT","BK4539"],"gpt_icon":0},{"id":"2542460303","title":"Keros Therapeutics Hindered by KER-065 Concerns Despite 'Intriguing' Pipeline, BofA Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2542460303","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542460303?lang=en_us&edition=fundamental","pubTime":"2025-06-11 00:11","pubTimestamp":1749571901,"startTime":"0","endTime":"0","summary":"Keros Therapeutics'  near-term upside remains limited due to uncertainty surrounding the development of its lead drug candidate, KER-065, despite an \"intriguing\" pipeline and strong cash position, BofA Securities said Monday in a report.Following a review, Keros plans to return $375 million in excess capital to shareholders and move ahead with the development of KER-065 for Duchenne muscular dystrophy. On Monday, activist shareholder ADAR1 Capital Management said the company should return $475 million to investors via a special dividend by the end of Q3.\"To be fair, there were limitations over what the board could do short of dissolving the company,\" BofA said.BofA downgraded Keros stock to neutral from buy and lowered the price target to $18 from $32.Keros shares fell 1.9% in recent Tuesday trading.Price: 13.83, Change: -0.26, Percent Change: -1.85","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","KROS","BK4539","BK4007","BK4139"],"gpt_icon":0},{"id":"2542349337","title":"Vera Therapeutics Inc call volume above normal and directionally bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=2542349337","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542349337?lang=en_us&edition=fundamental","pubTime":"2025-06-11 00:10","pubTimestamp":1749571812,"startTime":"0","endTime":"0","summary":"Bullish option flow detected in Vera Therapeutics (VERA) Inc with 6,061 calls trading, 4x expected, and implied vol increasing almost 3 points to 6...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-inc-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vera-therapeutics-inc-call-volume-above-normal-and-directionally-bullish-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4588","LENZ","BK4139","VERA","BK4585","BK4539"],"gpt_icon":0},{"id":"2542411310","title":"BofA Securities Downgrades Keros Therapeutics to Neutral From Buy, Adjusts Price Target to $18 From $32","url":"https://stock-news.laohu8.com/highlight/detail?id=2542411310","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542411310?lang=en_us&edition=fundamental","pubTime":"2025-06-10 21:50","pubTimestamp":1749563422,"startTime":"0","endTime":"0","summary":"Keros Therapeutics (KROS) has an average rating of overweight and mean price target of $24, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ma","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KROS","LENZ"],"gpt_icon":0},{"id":"2542483373","title":"Buy Rating for Unicycive Therapeutics: Strong Market Potential Despite Vendor Compliance Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2542483373","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542483373?lang=en_us&edition=fundamental","pubTime":"2025-06-10 21:45","pubTimestamp":1749563132,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Swayampakula Ramakanth has reiterated their bullish stance on UNCY stock, giving a Buy rating on June 4. Swayampakula Ramak...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-for-unicycive-therapeutics-strong-market-potential-despite-vendor-compliance-issue-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-for-unicycive-therapeutics-strong-market-potential-despite-vendor-compliance-issue-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","UNCY"],"gpt_icon":0},{"id":"2542734881","title":"Unicycive Therapeutics Faces FDA Compliance Delay","url":"https://stock-news.laohu8.com/highlight/detail?id=2542734881","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542734881?lang=en_us&edition=fundamental","pubTime":"2025-06-10 21:44","pubTimestamp":1749563041,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics ( ($UNCY) ) has issued an announcement. On June 10, 2025, Unicycive Therapeutics announced an update on its New Drug Applica...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/unicycive-therapeutics-faces-fda-compliance-delay?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/unicycive-therapeutics-faces-fda-compliance-delay?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","UNCY","LENZ","BK4007"],"gpt_icon":0},{"id":"2542310381","title":"Ernexa Therapeutics announces 1-for-15 reverse stock split","url":"https://stock-news.laohu8.com/highlight/detail?id=2542310381","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542310381?lang=en_us&edition=fundamental","pubTime":"2025-06-10 21:35","pubTimestamp":1749562532,"startTime":"0","endTime":"0","summary":"Ernexa Therapeutics (ERNA) announced a reverse stock split of its issued and outstanding shares of common stock, par value $0.005 per share at a ra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-announces-1-for-15-reverse-stock-split-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/ernexa-therapeutics-announces-1-for-15-reverse-stock-split-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ERNA","BK4539","BK4139","LENZ"],"gpt_icon":0},{"id":"2542312727","title":"Keros Therapeutics Cut to Neutral From Buy by B of A Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2542312727","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542312727?lang=en_us&edition=fundamental","pubTime":"2025-06-10 21:07","pubTimestamp":1749560820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KROS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 10, 2025 09:07 ET (13:07 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","KROS"],"gpt_icon":0},{"id":"2542300314","title":"Windtree Therapeutics announces agreement to acquire Titan Environmental","url":"https://stock-news.laohu8.com/highlight/detail?id=2542300314","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542300314?lang=en_us&edition=fundamental","pubTime":"2025-06-10 20:10","pubTimestamp":1749557453,"startTime":"0","endTime":"0","summary":"Windtree Therapeutics (WINT) announced a significant step in its drive toward overall profitability through its entry into a binding agreement to a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/windtree-therapeutics-announces-agreement-to-acquire-titan-environmental-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/windtree-therapeutics-announces-agreement-to-acquire-titan-environmental-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","WINT","BK4007","TWI","BK4152","BK4139"],"gpt_icon":0},{"id":"2542313487","title":"Optimistic Outlook for Summit Therapeutics: Buy Rating Affirmed Despite OS Miss in HARMONi Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2542313487","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542313487?lang=en_us&edition=fundamental","pubTime":"2025-06-10 18:16","pubTimestamp":1749550562,"startTime":"0","endTime":"0","summary":"Summit Therapeutics (SMMT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yigal Nochomovit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/optimistic-outlook-for-summit-therapeutics-buy-rating-affirmed-despite-os-miss-in-harmoni-trial-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/optimistic-outlook-for-summit-therapeutics-buy-rating-affirmed-despite-os-miss-in-harmoni-trial-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","SMMF"],"gpt_icon":0},{"id":"2542639749","title":"Keros Therapeutics: Strategic Initiatives and Capital Return Signal Potential Upside","url":"https://stock-news.laohu8.com/highlight/detail?id=2542639749","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2542639749?lang=en_us&edition=fundamental","pubTime":"2025-06-10 17:25","pubTimestamp":1749547543,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on Keros Therapeutics (KROS – Research Report), with a price t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/keros-therapeutics-strategic-initiatives-and-capital-return-signal-potential-upside-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/keros-therapeutics-strategic-initiatives-and-capital-return-signal-potential-upside-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128525689.USD","LU0251131958.USD","LU0742534661.SGD","LU0477156953.USD","LU0072461881.USD","LU0106831901.USD","IE00B19Z3B42.SGD","KROS","LU0787776722.HKD","LU0149725797.USD","BK4585","LU2361045086.USD","LU0980610538.SGD","LU0211327993.USD","LENZ","LU0320765489.SGD","LU0128525929.USD","LU0683600562.USD","LU0256863811.USD","BK4139","LU1814569148.SGD","LU2361044865.SGD","LU0130102774.USD","LU1267930490.SGD","LU1267930573.SGD","LU0154236417.USD","LU1363072403.SGD","BK4588","LU0048573561.USD","LU0417517546.SGD","LU0211328371.USD","LU1035773651.USD","LU0708994859.HKD","LU0029864427.USD","LU2461242641.AUD","LU0162691827.USD","LU0310800379.SGD","LU0314106906.USD","LU0052756011.USD","BK4559","LU1267930227.SGD","IE0002270589.USD","BK4207","LU2236285917.USD","LU1280957306.USD","LU1506573853.SGD","BK4007","LU0640476718.USD","LU0208291251.USD","LU0310800965.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":4,"totalSize":205,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LENZ\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-05-08","symbol":"LENZ","fiscalQuarterEnding":"2024/03","expectedEps":-0.84,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715140800000,"reportTimeType":"pre","actualEps":-3.53},{"market":"US","date":"2024-03-22","symbol":"LENZ","defaultRemindTime":1711114200000,"type":"split","dateTimestamp":1711080000000,"forFactor":7,"toFactor":1,"ratio":7},{"date":"2024-03-22","symbol":"LENZ","amount":1.03,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-18","name":"Therapeutics","recordDate":"2024-03-21","payableDate":"2024-03-18","currency":"USD","dateTimestamp":1711080000000,"payDate":"2024-03-21"},{"market":"US","date":"2021-08-12","symbol":"LENZ","fiscalQuarterEnding":"2021/06","expectedEps":-1.11,"name":null,"time":"","type":"earning","dateTimestamp":1628740800000,"reportTimeType":"","actualEps":-3.45}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LENZ\",market:\"US\",,,undefined,":[{"executeDate":"2024-03-22","recordDate":"2024-03-18","paymentDate":"2024-03-21","value":1.03,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LENZ\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.5,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.5,"analysts":8,"updateTime":1742270400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/LENZ\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"LENZ","date":"2025-06-12","current":-17.687152,"percent":0.01049,"low":-18.842712,"twenty":-14.731931,"median":-10.381402,"eighty":-7.26342,"high":-5.069183,"avg":-10.818854,"sd":3.680067,"marketCap":844384620},"quantilePoints":[{"date":"2024-03-28","current":-7.959158,"twenty":-7.219077,"median":-6.108955,"eighty":-6.016992,"marketCap":556886354},{"date":"2024-04-05","current":-7.492045,"twenty":-7.873034,"median":-7.667213,"eighty":-6.662191,"marketCap":524203432},{"date":"2024-04-12","current":-7.929963,"twenty":-7.855517,"median":-7.667213,"eighty":-7.432197,"marketCap":554843672},{"date":"2024-04-19","current":-6.382653,"twenty":-7.855517,"median":-7.488396,"eighty":-6.783348,"marketCap":446581492},{"date":"2024-04-26","current":-5.638193,"twenty":-7.716113,"median":-7.451903,"eighty":-5.889996,"marketCap":394493084},{"date":"2024-05-03","current":-5.988527,"twenty":-7.671592,"median":-6.864363,"eighty":-5.803142,"marketCap":419005276},{"date":"2024-05-10","current":-5.317808,"twenty":-7.667213,"median":-6.108955,"eighty":-5.803142,"marketCap":393230653},{"date":"2024-05-17","current":-5.708011,"twenty":-7.597146,"median":-6.0013,"eighty":-5.749862,"marketCap":422084590},{"date":"2024-05-24","current":-5.428308,"twenty":-7.489126,"median":-6.006774,"eighty":-5.719496,"marketCap":401401679},{"date":"2024-05-31","current":-5.355793,"twenty":-7.479638,"median":-5.988527,"eighty":-5.522773,"marketCap":396039443},{"date":"2024-06-07","current":-5.193496,"twenty":-7.457742,"median":-5.904593,"eighty":-5.428999,"marketCap":384038248},{"date":"2024-06-14","current":-6.433167,"twenty":-7.451903,"median":-5.930138,"eighty":-5.428308,"marketCap":475706952},{"date":"2024-06-21","current":-6.236339,"twenty":-7.425628,"median":-5.992177,"eighty":-5.43107,"marketCap":461152311},{"date":"2024-06-28","current":-6.150011,"twenty":-7.389135,"median":-6.0013,"eighty":-5.439358,"marketCap":454768696},{"date":"2024-07-05","current":-6.098214,"twenty":-7.269437,"median":-6.014073,"eighty":-5.469746,"marketCap":450938528},{"date":"2024-07-12","current":-6.771573,"twenty":-6.771573,"median":-6.098214,"eighty":-5.493918,"marketCap":500730721},{"date":"2024-07-15","current":-7.261916,"twenty":-7.163847,"median":-6.103393,"eighty":-5.509112,"marketCap":536989651},{"date":"2024-08-02","current":-8.498134,"twenty":-7.266429,"median":-6.108573,"eighty":-5.524305,"marketCap":628403011},{"date":"2024-08-09","current":-8.328931,"twenty":-7.474529,"median":-6.146558,"eighty":-5.597209,"marketCap":615891126},{"date":"2024-08-16","current":-8.944708,"twenty":-7.671592,"median":-6.236339,"eighty":-5.641258,"marketCap":621424629},{"date":"2024-08-23","current":-8.79431,"twenty":-7.94748,"median":-6.352018,"eighty":-5.670717,"marketCap":610975896},{"date":"2024-08-30","current":-8.746816,"twenty":-8.006409,"median":-6.382653,"eighty":-5.719496,"marketCap":607676296},{"date":"2024-09-06","current":-9.451311,"twenty":-8.199004,"median":-6.419354,"eighty":-5.743293,"marketCap":656620360},{"date":"2024-09-13","current":-8.17293,"twenty":-8.352945,"median":-6.434893,"eighty":-5.773217,"marketCap":567806132},{"date":"2024-09-20","current":-8.7389,"twenty":-8.507104,"median":-6.459289,"eighty":-5.788545,"marketCap":607126363},{"date":"2024-09-27","current":-8.806184,"twenty":-8.638371,"median":-6.616182,"eighty":-5.792924,"marketCap":611800796},{"date":"2024-10-04","current":-8.897214,"twenty":-8.745233,"median":-7.269437,"eighty":-5.800953,"marketCap":618125029},{"date":"2024-10-11","current":-9.340491,"twenty":-8.850511,"median":-7.455552,"eighty":-5.81701,"marketCap":648921294},{"date":"2024-10-18","current":-10.417023,"twenty":-8.905129,"median":-7.492045,"eighty":-5.857882,"marketCap":723712222},{"date":"2024-10-25","current":-9.902504,"twenty":-9.0017,"median":-7.670862,"eighty":-5.904593,"marketCap":687966558},{"date":"2024-10-31","current":-10.939457,"twenty":-9.257377,"median":-7.718702,"eighty":-5.904593,"marketCap":760007820},{"date":"2024-11-08","current":-14.709443,"twenty":-9.419648,"median":-7.959158,"eighty":-5.955683,"marketCap":894466512},{"date":"2024-11-15","current":-15.344855,"twenty":-9.514636,"median":-8.00261,"eighty":-5.970448,"marketCap":933105265},{"date":"2024-11-22","current":-15.521232,"twenty":-9.76398,"median":-8.132103,"eighty":-5.988527,"marketCap":943830613},{"date":"2024-11-29","current":-16.100113,"twenty":-9.924668,"median":-8.17293,"eighty":-5.994366,"marketCap":979031755},{"date":"2024-12-06","current":-16.33076,"twenty":-10.388526,"median":-8.285117,"eighty":-6.004584,"marketCap":993057210},{"date":"2024-12-13","current":-13.920266,"twenty":-10.815972,"median":-8.351032,"eighty":-6.018452,"marketCap":846477455},{"date":"2024-12-20","current":-13.694141,"twenty":-11.182468,"median":-8.50374,"eighty":-6.082845,"marketCap":832727009},{"date":"2024-12-27","current":-14.476534,"twenty":-12.093039,"median":-8.531114,"eighty":-6.098214,"marketCap":880303552},{"date":"2025-01-03","current":-12.794163,"twenty":-13.449021,"median":-8.618187,"eighty":-6.102358,"marketCap":778000234},{"date":"2025-01-10","current":-11.912274,"twenty":-13.190334,"median":-8.707238,"eighty":-6.108649,"marketCap":724373495},{"date":"2025-01-17","current":-10.130408,"twenty":-13.019383,"median":-8.746816,"eighty":-6.115785,"marketCap":616019980},{"date":"2025-01-24","current":-11.197719,"twenty":-12.871045,"median":-8.79431,"eighty":-6.143105,"marketCap":680922085},{"date":"2025-01-31","current":-11.523339,"twenty":-12.794163,"median":-8.877425,"eighty":-6.150011,"marketCap":700722728},{"date":"2025-02-07","current":-12.070562,"twenty":-12.328345,"median":-8.905129,"eighty":-6.232886,"marketCap":733998807},{"date":"2025-02-14","current":-11.432889,"twenty":-12.292165,"median":-8.964497,"eighty":-6.236339,"marketCap":695222549},{"date":"2025-02-21","current":-11.279124,"twenty":-12.151063,"median":-8.998138,"eighty":-6.308164,"marketCap":685872246},{"date":"2025-02-28","current":-9.62841,"twenty":-12.079607,"median":-9.059485,"eighty":-6.342695,"marketCap":585493990},{"date":"2025-03-07","current":-10.297741,"twenty":-11.943932,"median":-9.320702,"eighty":-6.355126,"marketCap":626195310},{"date":"2025-03-14","current":-11.193196,"twenty":-11.879712,"median":-9.419648,"eighty":-6.365485,"marketCap":680647077},{"date":"2025-03-21","current":-14.554795,"twenty":-11.943932,"median":-9.482973,"eighty":-6.379634,"marketCap":724377586},{"date":"2025-03-28","current":-14.68208,"twenty":-12.421509,"median":-9.574004,"eighty":-6.398202,"marketCap":730712447},{"date":"2025-04-04","current":-12.728528,"twenty":-13.089934,"median":-9.668992,"eighty":-6.415901,"marketCap":633486102},{"date":"2025-04-11","current":-10.2603,"twenty":-12.90813,"median":-9.741473,"eighty":-6.42488,"marketCap":510644883},{"date":"2025-04-17","current":-12.761733,"twenty":-12.945214,"median":-9.779811,"eighty":-6.430405,"marketCap":635138674},{"date":"2025-04-25","current":-15.833323,"twenty":-13.271407,"median":-9.84549,"eighty":-6.435239,"marketCap":788008663},{"date":"2025-05-02","current":-15.982746,"twenty":-13.932929,"median":-9.940463,"eighty":-6.440764,"marketCap":795445305},{"date":"2025-05-09","current":-15.25222,"twenty":-14.136351,"median":-10.102399,"eighty":-6.452984,"marketCap":728141003},{"date":"2025-05-16","current":-16.118891,"twenty":-14.245886,"median":-10.138549,"eighty":-6.460191,"marketCap":769515850},{"date":"2025-05-23","current":-16.637714,"twenty":-14.356129,"median":-10.19625,"eighty":-6.460792,"marketCap":794284465},{"date":"2025-05-30","current":-17.410053,"twenty":-14.523491,"median":-10.236057,"eighty":-6.585104,"marketCap":831155927},{"date":"2025-06-06","current":-17.864023,"twenty":-14.65894,"median":-10.342966,"eighty":-6.96771,"marketCap":852828466},{"date":"2025-06-12","current":-17.687152,"twenty":-14.731931,"median":-10.381402,"eighty":-7.26342,"marketCap":844384620}],"updateTime":1749873615275}}}